BACKGROUND/AIMS: @entity977 are the third most common primary @entity1313 , after @entity816 and @entity1653 , and about 30% of them secrete @entity2124 ( @entity2124 ). Other subtypes of @entity977 are characterized by well-known gender-related differences, not only in clinical presentation and other biological characteristics but also in surgical outcome. For @entity2124 -releasing @entity977 , however, detailed data on gender differences of postsurgical treatment are not available. @entity1 AND METHODS: The @entity1 charts of a series of 18 @entity1 with @entity2012 who met strict immunohistochemical and electron microscopic criteria and who underwent surgical resection of their tumors between January 1990 and June 1999 were retrospectively reviewed. RESULTS: There were eight @entity1 and ten @entity1 ; the male-to-female-ratio was 1.3:1. The @entity1 and @entity1 were equal in age at surgery. @entity1 demonstrated higher @entity442 and smaller @entity2124 levels pre- and postoperatively, whereas the reduction in @entity442 was more pronounced compared to @entity1 (58% vs. 27%). The overall outcome was better in @entity1 than in @entity1 . Mixed @entity2124 - and prolactin-secreting @entity652 showed a worse outcome among all other histological subtypes. Mitose- and @entity1758 labeling index was increased in @entity1 compared to @entity1 . CONCLUSION: The clinical course and @entity5 biology of @entity2124 -releasing @entity977 appear to differ in @entity1 and @entity1 . @entity1 demonstrated a shorter preoperative duration of symptoms, larger and more @entity3 , and a worse clinical outcome. These findings suggest that therapy for @entity2124 -releasing @entity652 should be more aggressive in @entity1 than in @entity1 . The gender-related differences in @entity2124 -releasing @entity977 appear to have a basis in different biologic behavior, which warrants further investigation.

Gender-related differences in XXXX -releasing @entity977 . A clinicopathological study.

@entity1 :: ('9606', 'Species') :: ['men', 'women', 'patients', 'patient', 'PATIENTS', 'Men'] @entity1313 :: ('MESH:D001932', 'Disease') :: ['intracranial neoplasm'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity442 :: ('3479', 'Gene') :: ['IGF-1'] @entity2124 :: ('2688', 'Gene') :: ['GH', 'growth hormone'] @entity2012 :: ('MESH:D000172', 'Disease') :: ['acromegaly'] @entity1653 :: ('MESH:D008579', 'Disease') :: ['meningiomas'] @entity816 :: ('MESH:D001254', 'Disease') :: ['astrocytomas'] @entity977 :: ('MESH:D010911', 'Disease') :: ['pituitary adenomas', 'pituitary tumors', 'Pituitary adenomas'] @entity3 :: ('MESH:D009362', 'Disease') :: ['invasive tumors'] @entity1758 :: ('57534', 'Gene') :: ['MIB-1'] @entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas']
@entity2124 :: (2688,Gene) :: ['growth hormone']
